Factors influencing platelet recovery after blood cell transplantation in multiple myeloma

被引:16
作者
Gertz, MA
Lacy, MQ
Inwards, DJ
Pineda, AA
Chen, MG
Gastineau, DA
Tefferi, A
Kyle, RA
Litzow, MR
机构
[1] MAYO CLIN & MAYO FDN,DIV TRANSFUS MED,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DIV RADIAT ONCOL,ROCHESTER,MN 55905
关键词
hematopoietic stem cell; leukapheresis; melphalan; multiple myeloma; stem cell transplantation;
D O I
10.1038/sj.bmt.1700897
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We sought to determine factors that impact on the recovery of platelets after blood cell transplantation in patients with multiple myeloma, We performed retrospective analyses in 51 patients undergoing blood cell transplantation for multiple myeloma, The proportional-hazards model was applied to determine significant risk factors, Of 51 transplants, 14 patients failed to achieve a platelet count of 50 x 10(9)/l. Median time to a neutrophil count of 0.5 x 10(9)/l was 10.5 days, Median time to achieve a platelet count of 50 x 10(9)/l was 32 days. Multivariate analysis revealed that cyclophosphamide and G-CSF priming before collection of hematopoietic precursors (P < 0.001) was a positive predictor of rapid engraftment and prior exposure to melphalan given orally (P = 0.02) was a negative predictor of subsequent platelet engraftment, The number of mononuclear cells collected, the patient's disease status at the time of transplant and the presence of circulating plasma cells in the harvested product did not have a significant impact on time to platelet engraftment, We conclude that cyclophosphamide and G-CSF priming shortened the time to achieve platelet engraftment compared with G-CSF alone, Prior exposure to melphalan delayed platelet engraftment and can lead to complete failure of platelet recovery, Stem cells should be collected before melphalan administration in patients with multiple myeloma who are candidates for possible blood cell transplantation.
引用
收藏
页码:375 / 380
页数:6
相关论文
共 42 条
  • [1] ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737
  • [2] BARBOT C, 1994, NOUV REV FR HEMATOL, V36, P325
  • [3] Barlogie B, 1994, J Hematother, V3, P149, DOI 10.1089/scd.1.1994.3.149
  • [4] Bender J G, 1992, J Hematother, V1, P329, DOI 10.1089/scd.1.1992.1.329
  • [5] FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS
    BENSINGER, W
    APPELBAUM, F
    ROWLEY, S
    STORB, R
    SANDERS, J
    LILLEBY, K
    GOOLEY, T
    DEMIRER, T
    SCHIFFMAN, K
    WEAVER, C
    CLIFT, R
    CHAUNCEY, T
    KLARNET, J
    MONTGOMERY, P
    PETERSDORF, S
    WEIDEN, P
    WITHERSPOON, R
    BUCKNER, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) : 2547 - 2555
  • [6] High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma
    Bensinger, WI
    Rowley, SD
    Demirer, T
    Lilleby, K
    Schiffman, K
    Clift, RA
    Appelbaum, FR
    Fefer, A
    Barnett, T
    Storb, R
    Chauncey, T
    Maziarz, RT
    Klarnet, J
    McSweeney, P
    Holmberg, L
    Maloney, DG
    Weaver, CH
    Buckner, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1447 - 1456
  • [7] BERENSON J, 1995, J CELL BIOCH SA, V21, P361
  • [8] BERENSON JR, 1995, CANC INVEST S1, V13, P8
  • [9] BOIRON JM, 1993, BONE MARROW TRANSPL, V12, P49
  • [10] COMPARATIVE-STUDY OF PERIPHERAL-BLOOD PROGENITOR-CELL COLLECTION IN PATIENTS WITH MULTIPLE-MYELOMA AFTER SINGLE-DOSE CYCLOPHOSPHAMIDE COMBINED WITH RHGM-CSF OR RHG-CSF
    DEMUYNCK, H
    DELFORGE, M
    VERHOEF, G
    ZACHEE, P
    VANDENBERGHE, P
    BOOGAERTS, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (02) : 384 - 392